RNA技術促進醫藥品探索·開發 (Drug Discovery and Development)

本報告提供RNA治療藥產業相關之產業推動因素與課題，技術概要與趨勢，臨床實驗平台分析，IP形勢概要，創新者的簡介，及未來發展藍圖等觀點下的總括性分析資訊。

第1章 摘要整理

第2章 RNA治療藥:產業概要

• RNA是變革治療平台的新星
• 產業的推動因素與課題
• RNA輸送(給藥):技術區分
• RNA治療藥:技術區分
• RNA治療藥整體分子的考察

第3章 技術趨勢·臨床實驗平台

• SSO治療引起的選擇性splicing
• SMA和DMD SSO療法的臨床管道分析
• ASO的轉錄後修飾
• ASO療法的臨床管道概述
• ASO治療的新興臨床管道
• 早期ASO療法
• 核酸適體的配體結合之阻礙
• 核酸適體治療藥物臨床實驗平台分析
• RNA干擾療法平台的標誌性年份
• RNA干擾療法臨床分析
• mRNA治療藥的新興形勢概要
• mRNA治療藥的臨床實驗平台分析
• saRNA:RNA型治療藥的參與企業越來越多

第4章 專利形勢概要

• ASO技術的專利趨勢
• RNAi平台的專利趨勢
• mRNA技術的專利趨勢

第5章 革新的簡介

• 用於增強疾病管理的標的型RNAi技術
• 實現RNAi治療的標的型輸送(給藥)
• 開發穩定和非免疫原性mRNA療法
• 加強新型RNA治療和輸送(給藥)平台
• 實現強效反義治療

第6章 未來展望

• RNA平台可能改變衛生保健的未來
• RNA技術的未來情勢

第7章 成長機會·推薦行動

• 成長機會1:ASO治療藥
• 成長機會2:RNAi治療藥
• 成長機會3:mRNA治療藥
• 成功·成長的策略要求

第8章 主要產業的影響者

Redefining the Future of Healthcare through Groundbreaking RNA Therapies

This research service encompasses a comprehensive analysis of RNA therapy industry from the following perspectives:

• Industry Drivers and Challenges
• Technology Snapshot and Trends
• Clinical Pipeline Analysis
• Overview of the IP Landscape
• Innovator Profiles
• Future Roadmap

The RNA therapy platforms covered include:

• Splice-Switching Oligonucletides (SSO)
• Other Anti-Sense Oligonucleotide (ASO)
• Aptamers
• RNA-interference
• mRNA
• saRNA

An appendix is included, comprising lists of major industry influencers found in the study.

Table of Contents

1.0. EXECUTIVE SUMMARY

• 1.1. Research Scope: RNA Therapies Redefining the Healthcare Landscape
• 1.2. Analysis Framework: Frost & Sullivan's Core Value
• 1.3. Research Methodology: Five Steps Towards Success
• 1.4. Key Findings

2.0. RNA THERAPIES: INDUSTRY OVERVIEW

• 2.1. RNA is the Rising Star of Transformative Therapy Platforms
• 2.2. Industry Accelerators and Challenges
• 2.3. RNA Delivery: Technology Segmentation
• 2.4. RNA Therapies: Technology Segmentation
• 2.5. Molecular Insights Across RNA Therapy

3.0. TECHNOLOGY TRENDS & CLINICAL PIPELINE

• 3.1. Alternative Splicing Induced by SSO Therapies
• 3.2. Clinical Pipeline Analysis for SSO Therapies for SMA and DMD
• 3.3. Post-transcriptional Modifications by ASO
• 3.4. Clinical Pipeline Overview for ASO Therapies
• 3.5. Emerging Clinical Pipeline for ASO Therapies
• 3.6. Early Phase ASO Therapies
• 3.7. Inhibition of Ligand Binding by Aptamer
• 3.8. Clinical Pipeline Analysis for Aptamer Therapies
• 3.9. Landmark Year for RNA Interference Therapy Platform
• 3.10. Clinical Analysis of RNA Interference Therapeutics
• 3.11. Overview of the Emerging Landscape for mRNA Therapies
• 3.12. Clinical Pipeline Analysis of mRNA Therapies
• 3.13. saRNA: The Rising Participant in RNA-based Therapies

4.0. OVERVIEW OF THE PATENT LANDSCAPE

• 4.1. Patenting Trends for ASO Technologies
• 4.2. Patenting Trends for RNAi Platforms
• 4.3. Patenting Trends for mRNA Technologies

5.0. INNOVATION PROFILES

• 5.1. Targeted RNAi Technology for Enhanced Disease Management
• 5.2. Enabling Targeted Delivery of RNAi Therapeutics
• 5.3. Developing Stable and Non-immunogenic mRNA Therapies
• 5.4. Fueling Novel RNA Therapy and Delivery Platforms
• 5.5. Enabling Potent Antisense Therapeutics

6.0. FUTURE PERSPECTIVES

• 6.1. RNA Platforms likely to Transform the Future of Health & Wellness
• 6.2. Navigating Through The Future Landscape for RNA Technologies

7.0. GROWTH OPPORTUNITIES AND COMPANIES TO ACTION

• 7.1. Growth Opportunity 1: ASO Therapies
• 7.2. Growth Opportunity 2: RNAi Therapies
• 7.3. Growth Opportunity 3: mRNA Therapies
• 7.4. Strategic Imperatives for Success and Growth

8.0. KEY INDUSTRY INFLUENCERS

• 8.1. Industry Interactions
• 8.1. Industry Interactions (continued)